tldrdailynews.com logo
Tag

Orforglipron

All articles tagged with #orforglipron

New pill could sustain weight loss after GLP-1 injections
health14 days ago

New pill could sustain weight loss after GLP-1 injections

Orforglipron, a once-daily small-molecule pill that targets the GLP-1 system and has FDA approval for obesity, may help people keep most of their weight loss after stopping injections like Wegovy or Mounjaro. In a randomized trial, those who switched to orforglipron regained about 26% of lost weight (vs over 50% on placebo) after 52 weeks, with more than two-fifths maintaining at least 80% of their weight loss and improved health markers such as blood sugar, blood pressure, insulin and cholesterol. The pill could be cheaper and easier to store than peptide injections, but it is not yet licensed in the UK for weight loss, and US monthly costs are roughly $149–$299.

via The Conversation|
#glp-1#health#obesity
New Pill Could Sustain GLP-1 Weight Loss and Lower Costs
health14 days ago

New Pill Could Sustain GLP-1 Weight Loss and Lower Costs

Orforglipron, a once-daily pill-based GLP-1 weight‑loss drug, could sustain weight loss and cut costs versus injections like Wegovy and Mounjaro. In a small trial, switching to orforglipron after initial weight loss reduced weight regain markedly (about 26% with orforglipron vs 50%+ on placebo for Mounjaro; about 21% vs 62% for Wegovy) while preserving health benefits; US monthly price is roughly $149–$299 vs over $1,000 for Mounjaro, and the UK has not yet licensed it but expects approval around late 2026–early 2027.

via ScienceAlert|
#affordability#glp-1#health
New daily pill may lock in weight loss after obesity injections
health22 days ago

New daily pill may lock in weight loss after obesity injections

A new daily pill, orforglipron, could help people maintain weight loss after stopping GLP-1 obesity injections. In a Nature Medicine trial, participants who took orforglipron for a year kept more than 70% of their earlier weight loss, versus about 38-50% for those on placebo; side effects were mostly mild. The long-term durability, duration of treatment, and cost (UK pricing not yet known) remain unclear, but experts say this supports the view that obesity is a chronic condition requiring ongoing management.

via BBC|
#clinical-trial#glp-1#health
Lilly’s Foundayo earns non-inferiority and cardiometabolic gains in ACHIEVE-4, fueling FDA submission
healthcare1 month ago

Lilly’s Foundayo earns non-inferiority and cardiometabolic gains in ACHIEVE-4, fueling FDA submission

In ACHIEVE-4, the largest/longest Phase 3 trial of Foundayo (orforglipron) vs insulin glargine in adults with type 2 diabetes at high CV risk, Foundayo met non-inferiority for MACE-4 and showed 16% lower risk for MACE-4 and 23% lower risk for MACE-3; a pre-planned analysis also showed 57% lower risk of all-cause death. The study (2,700+ participants across 15 countries) demonstrated sustained A1C and body-weight improvements through 104 weeks. Lilly intends to submit Foundayo to the FDA for type 2 diabetes by end of Q2.

via Eli Lilly|
#achieve-4#cardiovascular-safety#foundayo
New Oral GLP-1 Pill Shifts the Weight-Loss Race Against Ozempic
health2 months ago

New Oral GLP-1 Pill Shifts the Weight-Loss Race Against Ozempic

A 52-week phase-3 trial in 1,698 adults with type 2 diabetes across six countries found orforglipron, a daily oral small-molecule GLP-1 drug, reduced HbA1c more and produced greater weight loss than oral semaglutide (1.71–1.91% vs 1.47% HbA1c and 6.1–8.2 kg vs 5.3 kg), but caused more gastrointestinal side effects and higher discontinuation (~10% vs 4–5%). It’s cheaper to manufacture and doesn’t require refrigeration, giving it logistical advantages, though long-term comparisons with injectable GLP-1 therapies and obesity trials without diabetes are still underway.

via ScienceAlert|
#diabetes#glp-1#health
Lilly’s Orforglipron Edges Novo’s GLP-1 Pill in Major Diabetes Trial
business3 months ago

Lilly’s Orforglipron Edges Novo’s GLP-1 Pill in Major Diabetes Trial

In a year-long, head-to-head trial with 1,698 diabetes patients, Eli Lilly’s oral GLP-1 pill orforglipron outperformed Novo Nordisk’s Rybelsus on blood sugar control and weight loss (roughly 15–20 lbs vs 8–11 lbs), with better cardiovascular markers. Higher doses brought more GI side effects (about 10% dropout). The pill can be taken anytime, doesn’t require refrigeration, and Lilly aims for U.S. availability by mid-2026 at about $145–$399 out of pocket.

via Business Insider|
#business#diabetes#glp-1
Medicare tailwinds could accelerate Lilly’s obesity-pill rollout
business4 months ago

Medicare tailwinds could accelerate Lilly’s obesity-pill rollout

Eli Lilly CEO Dave Ricks says Medicare coverage of obesity treatments later this year could be a major catalyst for the launch of orforglipron, with a full rollout planned in Q2 and price reductions expected in the second half under Trump-era deals; the move could expand access to 20–30 million beneficiaries and follows strong early demand for competitor Wegovy, a GLP-1 obesity pill.

via CNBC|
#business#eli-lilly#glp-1
Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss
health4 months ago

Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss

Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.

via Gizmodo|
#cagrisema#glp-1-therapy#health
Eli Lilly's forforglipron Shows Promising Results in Weight Loss and Obesity Treatment
health9 months ago

Eli Lilly's forforglipron Shows Promising Results in Weight Loss and Obesity Treatment

Eli Lilly's experimental oral GLP-1 pill, orforglipron, helped overweight adults with type 2 diabetes lose an average of 10.5% of their body weight in a late-stage trial, with significant improvements in blood sugar levels, positioning it as a promising alternative to injectable obesity drugs and potentially paving the way for regulatory approval and market launch next year.

via Reuters|
#glp-1-pill#health#lilly